BioRender
-46%
est. 2Y upside i
'Figma/Canva for scientists’
Rank
#3209
Sector
Life Sciences Software
Est. Liquidity
~3Y
Data Quality
Data: MediumGiven the high entry valuation of $900M (24.7x revenue) and modest growth of 18.6% YoY, the expected equity return over 2 years is negative (-45.8%).
Last updated: July 19, 2026
If BioRender capitalizes on an IPO window or expands category leadership, exit multiple could expand to 15x, implying a $750M exit, a 16.7% decline from entry.
Base case assumes exit multiple converges to 10x (midpoint of comp range), yielding $500M exit, a 44.4% depreciation.
In bear case, multiple compresses to 5x due to slowing growth or incumbent competition, resulting in $250M exit, a 72.2% loss.
Preference Stack Risk
lowFunding Intensity
8%Total liquidation preference of $72M represents only 8% of current valuation, so common stock retains significant value even in moderate downside.
Dilution Risk
lowCompany is profitable with $36.5M revenue, so no near-term dilution expected.
Secondary Liquidity
limitedA $30M secondary investment in Dec 2025 provided some liquidity, but ongoing secondary opportunities are likely restricted.
Questions to Ask at the Interview
Strategic questions based on BioRender's data — designed to show you've done your homework.
- 1
“How does BioRender plan to expand beyond academic customers into biotech and pharmaceutical enterprise?”
- 2
“What is the revenue retention rate and expansion strategy?”
- 3
“What is the expected timeline for an IPO or liquidity event, and how would that affect employee equity?”
Community
Valuation Sentiment
Our model estimates -46% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.